To access this material please log in or register

Register Authorize

Prospects of the statin treatment: Review of current studies

Gordeev I. G., Taratukhin E. O.
Federal State Budgetary Educational Institution of Higher Education, "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation, Ostrovityanova 1, Moscow 117997

Keywords: dyslipidemia, ischaemic heart disease, diabetes mellitus, atherosclerosis, HIV infection, heart failure, inflammation

DOI: 10.18087/rhj.2016.6.2271

The article present a review of last-year publications on statins, specifically rosuvastatin, studies. This drug group demonstrates various clinical effects, which array has been expanding. The review provides significant current evidence on the effect of statins on lipid metabolism, activity of the coagulation system, and the development of DM. Data from translational studies are presented.
  1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34 (38):2949–3003.
  2. Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A et al. Rosuvastatin: beyond the cholesterol-lowering effect. Pharmacol Res. 2016 May;107:1–18.
  3. Chiang CE, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J et al. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016 May 2;23 (5):567–87.
  4. Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016 May 1;37 (17):1373–9.
  5. Vavlukis M, Mladenovska K, Daka A, Dimovski A, Domazetovska S, Kuzmanovska S, Kedev S. Effects of rosuvastatin versus atorvastatin, alone or in combination, on lipoprotein (a). Ann Pharmacother. 2016 Aug;50 (8):609–15.
  6. Pytel E, Jackowska P, Chwatko G, Olszewska-Banaszczyk M, Koter-Michalak M, Kubalczyk P, Broncel M. Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases. Pharmacol Rep. 2016 Apr;68 (2):344–8.
  7. Macpherson M, Hamren B, Braamskamp MJ, Kastelein JJ, Lundstrom T, Martin PD. Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. Eur J Clin Pharmacol. 2016 Jan;72 (1):19–27.
  8. Konyi A, Sarszegi Z, Hild G, Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. J Comp Eff Res. 2016 Jul;5 (4):355–64.
  9. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016 May 1;117 (9):1444–8.
  10. Bando Y, Toyama H, Kanehara H, Hisada A, Okafuji K, Tanaka N. Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016 Jan;111:66–73.
  11. Duarte T, da Cruz IB, Barbisan F, Capelleto D, Moresco RN, Duarte MM. The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism. Pharmacogenomics J. 2016 Feb 16. [Epub ahead of print]
  12. Park DS, Yun KH, Park HY, Rhee SJ, Kim NH, Oh SK, Jeong JW. Antioxidative activity after rosuvastatin treatment in patients with stable ischemic heart disease and decreased high density lipoprotein cholesterol. Korean Circ J. 2016 May;46 (3):309–14.
  13. Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD. Plasma VEGF and IL-8 levels in patients with mixed dyslipidaemia. effect of rosuvastatin monotherapy or its combination at a lower dose with omega-3 fatty acids: a pilot study. Curr Vasc Pharmacol. 2016;14 (5):474–80.
  14. Wang X, Zhao X, Li L, Yao H, Jiang Y, Zhang J. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016 May;25 (5):459–65.
  15. Sukegawa H, Maekawa Y, Yuasa S, Anzai A, Kodaira M, Takei M et al. Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent. Coron Artery Dis. 2016 Aug;27 (5):405–11.
  16. Park SJ, Kang SJ, Ahn JM, Chang M, Yun SC, Roh JH et al. Effect of statin treatment on modifying plaque composition: a double-blind, randomized study. J Am Coll Cardiol. 2016 Apr 19;67 (15):1772–83.
  17. Liu T, Meng XY, Li T, Zhang DY, Zhou YH, Han QF et al. Rosuvastatin may stabilize vulnerable carotid plaques and reduce carotid intima media thickness in patients with hyperlipidemia. Int J Cardiol. 2016 Jun 1;212:20–1.
  18. Li Z, Wang L, Hu X, Zhang P, Chen Y, Liu X et al. Effect of rosuvastatin on atherosclerotic plaque stability: an intravascular ultrasound elastography study. Atherosclerosis. 2016 May;248:27–35.
  19. Du R , Zhao XQ, Cai J, Cui B, Wu HM, Ye P. Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy. J Clin Lipidol. 2016 May-Jun;10 (3):587–93.
  20. Jiao Y, Hu F, Zhang Z, Gong K, Sun X, Li A, Liu N. Efficacy and safety of loading-dose rosuvastatin therapy in elderly patients with acute coronary syndromes undergoing elective percutaneous coronary intervention. Clin Drug Investig. 2015 Dec;35 (12):777–84.
  21. San Norberto EM, Gastambide MV, Taylor JH, Garcia-Saiz I, Vaquero C. Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis. Vasa. 2016;45 (2):133–40.
  22. Gaertner S, Cordeanu EM, Nouri S, Mirea C, Stephan D. Statins and prevention of venous thromboembolism: Myth or reality? Arch Cardiovasc Dis. 2016 Mar;109 (3):216–22.
  23. Eschrich J, Meyer R , Kuk H, Wagner AH, Noppeney T, Debus S et al. Varicose remodeling of veins is suppressed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. J Am Heart Assoc. 2016 Feb 23;5 (2):e002405.
  24. Nurullahoglu-Atalik KE, Oz M, Shafiyi A. Rosuvastatin-induced responses in calf cardiac vein. Bratisl Lek Listy. 2015;116 (8):494–8.
  25. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016 Mar;115 (3):520–32.
  26. Verdoia M, Nardin M, Sartori C, Pergolini P, Rolla R , Barbieri L et al. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Atherosclerosis. 2015 Dec;243 (2):389–94.
  27. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016 Oct;25 (10):1131–49.
  28. Olotu BS, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM, Rasu RS. Use of statins and the risk of incident diabetes: a retrospective cohort study. Am J Cardiovasc Drugs. 2016 Oct;16 (5):377–90.
  29. Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A et al. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers. 2016 Jul 12;1–7. [Epub ahead of print]
  30. Bonsu KO, Reidpath DD, Kadirvelu A. Lipophilic statin versus rosuvastatin (hydrophilic) treatment for heart failure: a meta-analysis and adjusted indirect comparison of randomised trials. Cardiovasc Drugs Ther. 2016 Apr;30 (2):177–88.
  31. Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Wang XL et al. Synergistic inhibitory effect of rosuvastatin and angiotensin ii type 2 receptor agonist on vascular remodeling. J Pharmacol Exp Ther. 2016 Aug;358 (2):352–8.
  32. Hileman CO, Turner R , Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016 Jan 2;30 (1):65–73.
  33. Longenecker CT, Sattar A, Gilkeson R , McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016 Sep 10;30 (14):2195–203.
  34. Weiss L, Chevalier MF, Assoumou L, Paul JL, Alhenc-Gelas M, Didier C et al. Rosuvastatin is effective to decrease CD8 T-cell activation only in HIV-infected patients with high residual T-cell activation under antiretroviral therapy. J Acquir Immune Defic Syndr. 2016 Apr 1;71 (4):390–8.
  35. Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2016 Apr;32 (4):311–6.
  36. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016 Feb 6.pii:ehv734. [Epub ahead of print]
  37. Unlu M, Aktas Z, Gocun PU, Ilhan SO, Hasanreisoglu M, Hasanreisoglu B. Neuroprotective effect of systemic and/or intra-vitreal rosuvastatin administration in rat glaucoma model. Int J Ophthalmol. 2016 Mar 18;9 (3):340–7.
  38. Kata D, Foldesi I, Feher LZ, Hackler LJr, Puskas LG, Gulya K. Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells. Neuroscience. 2016 Feb 9;314:47–63.
  39. Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016 un;76 (9):947–56.
  40. Zhou YY, Zhu GQ, Wang Y, Zheng JN, Ruan LY, Cheng Z et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016 Apr 19;7 (16):21753–62.
  41. Zhong GC, Liu Y, Ye YY, Hao FB, Wang K, Gong JP. Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep. 2016 May 20;6:26256.
  42. Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016 Apr;15 (4):344–53.
  43. Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT et al. Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer. 2016 Jun 28;115 (1):129–35.
  44. Neroldova M, Stranecky V, Hodanova K, Hartmannova H, Piherrova L, Pristoupilova A et al. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. Pharmacogenomics. 2016 Aug;17 (13):1405–14.
  45. Harada PH, Cook NR , Cohen DE, Paynter NP, Rose L, Ridker PM. Relation of alanine aminotransferase levels to cardiovascular events and statin efficacy. Am J Cardiol. 2016 Jul 1;118 (1):49–55.
Gordeev I.G., Taratukhin E.O. Prospects of the statin treatment: Review of current studies. Russian Heart Journal. 2016;15 (6):398–403

To access this material please log in or register

Register Authorize
Ru En